Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.14
Nov 19 • 2:24 PM ET Dollar change-0.16 Percentage change(-12.31%)
Nov 17, 8:50 AMMAIA reported an 88% disease control rate (38 of 43 patients) in updated interim data from its Phase 2 THIO-101 study and said Part C enrollment is complete.
Index
-
Market Cap
70.40M
Enterprise Value
49.06M
Income
-25.12M
Sales
0.00M
Book/sh
0.25
Cash/sh
0.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13
IPO
Jul 28, 2022
P/E
-
Forward P/E
22.80
PEG
-
P/S
-
P/B
4.49
P/C
3.30
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
3.41
Current Ratio
3.41
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.48
EPS next Y
0.05
EPS next Q
-0.12
EPS this Y
27.14%
EPS next Y
109.80%
EPS next 5Y
-
EPS past 3/5Y
26.39% -2.25%
Sales past 3/5Y
- -
EPS Y/Y TTM
35.05%
Sales Y/Y TTM
-
EPS Q/Q
56.04%
Sales Q/Q
-
Insider Own
16.98%
Insider Trans
6.15%
Inst Own
19.80%
Inst Trans
7.59%
ROA
-144.03%
ROE
-319.77%
ROIC
-160.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
2.84%
SMA50
-2.91%
SMA200
-17.13%
Trades
Shs Outstand
61.74M
Shs Float
51.27M
52W High
3.19 -64.26%
52W Low
0.87 31.03%
Volatility
11.87% 7.22%
ATR (14)
0.09
RSI (14)
50.86
Beta
0.19
Rel Volume
1.95
Avg Volume
508.37K
Volume
767,357
Perf Week
12.87%
Perf Month
0.00%
Perf Quarter
-17.99%
Perf Half Y
-10.94%
Perf YTD
-25.49%
Perf Year
23.91%
Perf 3Y
-5.79%
Perf 5Y
-
Perf 10Y
-
Prev Close
1.30
Price
1.14
Change %
-12.31%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith StanDirectorNov 13 '26Buy1.0081,21881,2181,600,396Nov 17 04:07 PM
Smith StanDirectorNov 16 '26Buy1.0018,78218,7821,619,178Nov 17 04:07 PM
Vitoc VladChief Executive OfficerNov 13 '26Buy1.0060,40060,4001,109,521Nov 17 04:05 PM
Vitoc VladChief Executive OfficerNov 16 '26Buy1.0039,60039,6001,149,121Nov 17 04:05 PM
Vitoc VladChief Executive OfficerSep 14 '26Buy1.3773,000100,0101,049,121Sep 15 06:33 AM
Guerrero RamiroDirectorSep 10 '26Buy1.3237,59549,516773,296Sep 14 09:03 AM
Guerrero RamiroDirectorAug 27 '26Buy1.3978,239108,752689,081Sep 01 04:16 PM
Guerrero RamiroDirectorAug 28 '26Buy1.3546,62062,937735,701Sep 01 04:16 PM
Guerrero RamiroDirectorAug 26 '26Buy1.398,93112,414610,842Sep 01 04:16 PM
Guerrero RamiroDirectorAug 24 '26Buy1.331,7942,386601,911Aug 26 07:56 AM
Guerrero RamiroDirectorAug 20 '26Buy1.3711,89916,302600,117Aug 24 04:09 PM
Vitoc VladChief Executive OfficerJun 01 '26Buy1.3972,700100,886976,121Jun 02 09:02 AM
Smith StanDirectorJun 01 '26Buy1.3475,000100,2001,519,178Jun 02 09:01 AM
Gryaznov SergeiChief Scientific OfficerJun 01 '26Buy1.342,0002,69046,511Jun 02 09:00 AM
Smith StanDirectorDec 22 '25Buy1.2257,18969,9991,421,478Dec 23 08:18 AM
CHAOUKI STEVEN MDirectorDec 22 '25Buy1.2240,84949,999151,873Dec 23 08:16 AM
Louie Ngar YeeDirectorDec 22 '25Buy1.2281,699100,0001,248,888Dec 23 08:14 AM
Smith StanDirectorDec 05 '25Buy1.2013,74016,4414,580Dec 09 04:51 PM
Vitoc VladChief Executive OfficerNov 28 '25Buy1.1450,00056,830881,421Dec 01 06:20 AM
Vitoc VladChief Executive OfficerNov 26 '25Buy1.0522,00023,019853,421Dec 01 06:20 AM
Luput CristianDirectorNov 26 '25Buy1.0820,00021,616419,483Dec 01 06:18 AM
Luput CristianDirectorNov 28 '25Buy1.1118,14520,230437,628Dec 01 06:18 AM
Smith StanDirectorNov 26 '25Buy1.0415,00015,5821,364,289Dec 01 06:14 AM
Luput CristianDirectorNov 25 '25Buy0.9810,0009,785399,483Nov 28 06:52 AM
Vitoc VladChief Executive OfficerNov 25 '25Buy0.9710,50010,144831,421Nov 28 06:48 AM
Smith StanDirectorNov 25 '25Buy0.9815,00014,7001,349,289Nov 26 04:43 PM
Smith StanDirectorNov 24 '25Buy0.9910,0009,9001,334,289Nov 26 04:43 PM
Vitoc VladChief Executive OfficerNov 24 '25Buy0.9910,0009,891820,921Nov 25 04:15 PM
Vitoc VladChief Executive OfficerNov 21 '25Buy0.921,8001,656810,921Nov 25 04:15 PM
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.
M.D.Dr. Vlad Vitoc M.B.A.
Head of Finance and Principal Financial & Accounting OfficerMr. Jeffrey C. Himmelreich M.B.A.
Chief Scientific OfficerDr. Sergei M. Gryaznov Ph.D.
Company SecretaryLinda Moreira